ABSTRACT
OBJETIVO: Estimar a frequência de história pregressa de chiado, descrevendo as características clínicas e formas de tratamento utilizadas. MÉTODOS: Coorte retrospectiva incluindo lactentes (6-23 meses de vida) com sintomas de infecção de vias aéreas superiores e relato de episódio prévio de chiado. Os dados foram registrados em questionário anteriormente validado. RESULTADOS: Dos 451 avaliados, 164 (36,4%; IC95% = 31,9-41,0) apresentaram história pregressa de chiado, 148 (32,8%; IC95% = 28,5-37,4) no primeiro ano de vida. A média de idade no primeiro episódio de chiado foi de 5,3±3,9 meses. Para quem começou a chiar no primeiro ano de vida, 38,5% referiram entre três e seis episódios e 14,2% > seis episódios. A média da idade no primeiro episódio foi menor para os que apresentaram > três episódios em comparação aos que apresentaram até dois episódios (3,2±2,7 versus 5,7±2,5 meses, p < 0,001). CONCLUSÃO: Um terço dos lactentes apresentou chiado no primeiro ano de vida. Quanto mais cedo ocorre o primeiro episódio, mais frequente é a recorrência do chiado.
OBJECTIVE: To estimate the frequency and describe the clinical characteristics and respective treatments of previous history of wheezing. METHODS: Infants aged 6-23 months with upper respiratory tract complaints and reporting previous wheezing were followed-up retrospectively. Data were registered on a validated standardized form. RESULTS: Out of 451 infants, 164 (36.4%; 95%CI: 31.9-41.0) had a report of prior history of wheezing, 148 (32.8%; 95%CI: 28.5-37.4) during the first year of life. The mean age at the first episode of wheezing was 5.3±3.9 months. Among those who had had their first episode before 12 months of age, 38.5% reported 3 to 6 episodes and 14.2% > 6 episodes. Mean age at first episode was lower for those with > 3 episodes in comparison with those with < 2 episodes (3.2±2.7 vs. 5.7±2.5 months, p < 0.001). CONCLUSION: One third of the infants reported wheezing during the first year of life. The earlier the first episode occurs, the more frequently wheezing recurs.
Subject(s)
Female , Humans , Infant , Bronchodilator Agents/therapeutic use , Respiratory Sounds/drug effects , Respiratory Sounds/etiology , Asthma/complications , Brazil/epidemiology , Prevalence , Recurrence , Retrospective Studies , Severity of Illness IndexABSTRACT
All children aged from 4 weeks to <5 year, were intubated for at least 48 hours [n=51] during 6 months. Data of the patients treated with DEX (0.5 ml/kg every 6 hours for 3 doses, beginning 6-12 hours prior to extubation) (n=30) were compared with control patients (who had not received medication) (n=21). The DEX and control groups were similar in age i.e., mean ages of DEX group were 16.85±14 months, and that of control group were 19.02 ± 19 months, mean duration of intubation and mechanical ventilation in DEX group was 5.17 ± 4.58 days, and that in control group was 3.98 ± 3.60 days. There was no significant difference between DEX and control group in the incidence of postextubation stridor [17% (5/30) vs. 10% (2/ 21); p = 0.5] and the reintubation rate [7% (2/30) vs. 10% (2/21); p = 0.7]. Our data revealed that the prophylactic use of dexamethasone in planned extubation of high risk children were not effective.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Case-Control Studies , Child, Preschool , Device Removal/adverse effects , Device Removal/methods , Dexamethasone/therapeutic use , Female , Follow-Up Studies , Humans , Incidence , Infant , Intubation, Intratracheal/adverse effects , Intubation, Intratracheal/methods , Male , Probability , Reference Values , Respiration, Artificial/adverse effects , Respiration, Artificial/methods , Respiratory Sounds/drug effects , Respiratory Sounds/etiology , Retreatment , Retrospective Studies , Risk Assessment , Sensitivity and Specificity , Severity of Illness Index , Time FactorsABSTRACT
OBJETIVO: Estender a aplicação de um instrumento para avaliar a prevalência e as características clínicas da sibilância em lactentes. MÉTODOS: Estudo transversal, como parte do projeto Estudio Internacional de Sibilancias en Lactantes (EISL), aplicando questionário aos pais de lactentes entre 12 e 15 meses (grupo I) e 16 e 24 meses de vida (grupo II). RESULTADOS: Mil trezentos e sessenta e quatro lactentes (45,4%) do grupo I e 250 (46,7%) do grupo II apresentaram pelo menos um episódio de sibilância (p = 0,58). O uso de β2-agonistas inalados, corticoides inalatórios ou orais e modificadores de leucotrienos foi semelhante entre os grupos (p = 0,52, 0,12, 0,06 e 0,75). Sintomas noturnos, dificuldade para respirar, visitas à emergência, hospitalização por sibilância e diagnóstico médico de asma não foram diferentes nos grupos (p = 0,09, 0,28, 0,69, 0,54 e 0,45). CONCLUSÃO: A aplicação do questionário pode ser estendida aos lactentes com até 24 meses de vida.
OBJECTIVE: To verify the possibility of extending the application of an instrument to investigate the prevalence and clinical characteristics of wheezing in infants. METHODS: A cross-sectional study conducted as part of the International Study on Wheezing in Infants (EISL, Estudio Internacional de Sibilancias en Lactantes). A questionnaire was administered to parents of infants aged 12 to 15 months (group I) and 16 to 24 months (group II) infants. RESULTS: One thousand, three hundred and sixty-four infants (45.4%) in group I and 250 (46.7%) in group II had had at least one episode (p = 0.58). The numbers of patients on inhaled β2-agonists, inhaled or oral steroids and/or leukotriene modifiers were similar in both groups (p = 0.52, 0.12, 0.06, and 0.75). There were no differences between the groups in terms of night-time symptoms, shortness of breath, emergency room visits, asthma hospitalization or asthma diagnosed by a doctor (p = 0.09, 0.28, 0.54, and 0.45). CONCLUSION: The application of the questionnaire can be extended to include infants up to 24 months of age.